STOCK TITAN

Rubric Capital discloses 6.96% Nurix Therapeutics (NRIX) position in equity filing

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Rubric Capital Management LP and David Rosen reported beneficial ownership of Nurix Therapeutics, Inc. common stock. They collectively hold 7,227,778 shares of common stock, representing 6.96% of the class. The ownership is held through Rubric Capital–managed funds, including Rubric Capital Master Fund LP, which has rights to receive dividends and sale proceeds on more than 5% of the shares.

The percentage ownership is based on 103,781,683 shares outstanding of Nurix common stock as of June 30, 2026, as referenced from the company’s quarterly report. All reported voting and dispositive powers are shared, with no sole voting or dispositive power reported by the filing parties.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 7,227,778 shares Nurix Therapeutics common stock reported by Rubric Capital and David Rosen
Percent of class 6.96% Portion of Nurix common stock class beneficially owned by the reporting persons
Shares outstanding 103,781,683 shares Nurix common stock outstanding as of June 30, 2026, per quarterly report
Shared voting power 7,227,778 shares Shares over which the reporting persons have shared power to vote
Shared dispositive power 7,227,778 shares Shares over which the reporting persons have shared power to dispose
beneficial owner financial
"the beneficial owner of the Shares reported herein"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
shared voting power financial
"Shared Voting Power 7,227,778.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 7,227,778.00"
investment adviser financial
"the investment adviser to certain investment funds"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.
percent of class financial
"Percent of class: 6.96 %"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

What stake in Nurix Therapeutics (NRIX) does Rubric Capital report on this Schedule 13G?

Rubric Capital and David Rosen report beneficial ownership of 7,227,778 shares of Nurix Therapeutics common stock, representing 6.96% of the outstanding class, based on 103,781,683 shares outstanding as of June 30, 2026.

How many Nurix Therapeutics (NRIX) shares are outstanding for the 6.96% calculation?

The 6.96% ownership figure is based on 103,781,683 shares of Nurix Therapeutics common stock outstanding as of June 30, 2026, as reported in Nurix’s Quarterly Report for the period ended May 31, 2026.

Does Rubric Capital have sole or shared voting power over Nurix Therapeutics (NRIX) shares?

Rubric Capital and David Rosen report 0 shares with sole voting power and 7,227,778 shares with shared voting power. They likewise report shared dispositive power over the same 7,227,778 shares, with no sole dispositive power.

Who ultimately benefits from Rubric Capital’s Nurix Therapeutics (NRIX) holdings?

The Nurix shares are held for Rubric Funds advised by Rubric Capital. Rubric Capital Master Fund LP, one such fund, has the right to receive dividends or proceeds from the sale of more than 5% of Nurix’s common stock.

Who are the reporting persons for this Nurix Therapeutics (NRIX) ownership disclosure?

The reporting persons are Rubric Capital Management LP, investment adviser to the Rubric Funds holding Nurix shares, and David Rosen, Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital.

Where are Rubric Capital and David Rosen based in this Nurix Therapeutics (NRIX) filing?

The principal business office for both reporting persons is 155 East 44th St, Suite 1630, New York, NY 10017. Rubric Capital is a Delaware limited partnership, and David Rosen is a citizen of the United States.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





67080M103

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Rubric Capital Management LP
Signature:/s/ Michael Nachmani
Name/Title:Michael Nachmani / Chief Operating Officer
Date:08/14/2026
David Rosen
Signature:/s/ David Rosen
Name/Title:David Rosen / Individually
Date:08/14/2026